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Objective: We reviewed the incidence of stent-graft migration after endovascular aneurysm repair in a prospective
multicenter trial and identified factors that may predispose to such migration.
Methods: All patients who received treatment during the course of the multicenter AneuRx clinical trial were reviewed for
evidence of stent-graft migration over 5 years, from 1996 to 2001. Post-deployment distance from the renal arteries to
the proximal end of the stent graft and the proximal fixation length (length of the infrarenal neck covered by the stent
graft) were determined in patients for whom pre-procedure and post-procedure computed tomography scans were
measured in an independent core laboratory.
Results: Stent-graft migration was reported in 94 of 1119 patients, with mean time after device implantation of 30  11
months. Freedom from migration was 98.6% at 1 year, 93.4% at 2 years, and 81.2% at 3 years (Kaplan-Meier method).
Subset (n  387) analysis revealed that initial device deployment was lower in 47 patients with migration, as evidenced
by a greater renal artery to stent-graft distance (1.1 0.7 cm), compared with 340 patients without migration (0.8 0.6
cm; P  .006) on post-implantation computed tomography scan. Proximal fixation length was shorter in patients with
migration (1.6  1.4 cm) compared with patients without migration (2.3  1.4 cm; P  .005). There was significant
variation in migration rate among clinical sites (P < .001), ranging from 0% to 30% (median, 8%), with a greater than
twofold difference in migration rate between the lowest quartile (6%) and the highest quartile (15%) clinical sites.
Univariate and multivariate analysis revealed that renal artery to stent-graft distance (P  .001) and proximal fixation
length (P  .005) were significant predictors of migration, and that each millimeter increase in distance below the renal
arteries increased risk for subsequent migration by 5.8% and each millimeter increase in proximal fixation length
decreased risk for migration by 2.5%. Pre-implantation aortic neck length, neck diameter, degree of device oversizing,
correct versus incorrect oversizing, device type (stiff vs flexible), placement of proximal extender cuffs at the original
procedure, and post-procedure endoleak were not significant predictors of migration. Migration was treated with
placement of extender modules in 23 patients and surgical conversion in 7 patients; 64 patients (68%) with migration have
required no treatment.
Conclusions: Stent-graft migration among patients treated in the AneuRx clinical trial appears to be largely related to low
initial deployment of the device, below the renal arteries, and short proximal fixation length. Significant variation in
migration rate among clinical sites highlights the importance of the technical aspects of stent-graft deployment. Advances
in intraoperative imaging and deployment techniques that have been made since completion of the clinical trial facilitate
precision of device placement below the renal arteries and should increase proximal fixation length. Whether this,
together with increased iliac fixation length, will result in lower risk for migration remains to be determined in long-term
follow-up studies. (J Vasc Surg 2003;38:1264-72.)
Endovascular procedures to treat infrarenal abdominal
aortic aneurysm (AAA) are effective in preventing aneurysm
rupture, with reduced patient morbidity and mortality
compared with open surgical repair.1-3 However, migra-
tion of endoluminal devices noted after successful endovas-
cular repair raises concerns about long-term durability of
endovascular repair.4-6 Migration has been noted with all
current endovascular devices and configurations, including
those with modular design, unibody design, infrarenal fix-
ation, suprarenal fixation, hook and barb fixation, longitu-
dinal columnar support, and flexible designs.4-10 Risk for
migration increases over time, and can result in loss of
device fixation proximally, distally, or at modular junctions,
with subsequent aneurysm rupture.11-15 The purpose of
this investigation was to determine the incidence and sig-
nificance of stent-graft migration in the multicenter US
AneuRx clinical trial with follow-up to 5 years and to
identify factors that may predispose to stent-graft migra-
tion.
METHODS
Records for all patients who received treatment at 19
clinical sites (see Appendix) over the course of the US
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AneuRx clinical trial, from 1996 to 1999, were reviewed for
evidence of stent-graft migration with follow-up through
August 2001. This review included all patients who re-
ceived treatment during Phase I (n  40), Phase II (n 
424), and Phase III (n 639) of the clinical trial, as well as
all patients who did not meet inclusion criteria for the trial
but received the AneuRx stent graft on a compassionate-
use basis (n  90). Details of the study design and patient
eligibility have been published.1,16) Selection criteria in-
cluded abdominal aortic aneurysm with infrarenal neck
length of at least 10 mm and neck diameter between 18 and
26 mm, with maximum distal iliac diameter of 15 mm.
Patients were evaluated with pre-procedure and post-pro-
cedure contrast material–enhanced computed tomography
(CT), with scheduled follow-up imaging at 1, 6, and 12
months and at yearly intervals thereafter. Additional CT
scans were obtained at more frequent intervals as clinically
indicated. Abdominal x-ray films (kidneys, ureters, bladder)
were obtained at scheduled follow-up visits, and stent-graft
location and configuration in relation to the vertebral bod-
ies and femoral heads were noted. Follow-up angiograms
were obtained as clinically indicated, and were compared
with the post-deployment completion angiogram for evi-
dence of migration. The presence or absence of migration
was reported by each clinical site at each follow-up patient
visit. Migration was defined as any postimplantation
movement or displacement of the stent graft in relation
to the native aorta or renal arteries, as documented on
CT scans, abdominal x-ray films, angiograms, or patho-
logic analysis. Migration rate and factors that may pre-
dispose to migration, and clinical outcome were evalu-
ated in 1119 patients with more than one post-
implantation imaging study to allow assessment of
migration.
Preoperative, postoperative, and follow-up clinical and
imaging data from each clinical site were reported to a
centralized data registry and audited by external monitors.
Primary clinical end points included aneurysm rupture (in-
traoperative, perioperative, postoperative), aneurysm-re-
lated death (any death within 30 days of the primary
procedure or a secondary procedure, or related to aneurysm
rupture or to the device), surgical conversion (perioperative
and late open surgical aneurysm repair), and overall survival
(death from any cause).
An independent core laboratory evaluated preoperative
and postoperative CT scans and abdominal x-ray films from
13 clinical sites during Phase II of the trial, and was blinded
to patient information. In this subset of 387 patients the
distance from the lowermost renal artery to the beginning
of the aneurysm and the distance from the lowermost renal
Fig 1. Proximal fixation length calculated by subtracting axial distance from lowermost renal artery to top of stent graft
from axial distance from lowermost renal artery to beginning of aneurysm. Neck angulation was not measured, and can
influence effective fixation length (far right).
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artery to first appearance of the stent graft was determined
from serial axial CT scans. The proximal fixation length
(length of infrarenal neck covered by the stent graft) was
calculated by subtracting the distance from the lowermost
renal artery to the top of the stent graft from the length of
the infrarenal aortic neck (Fig 1). The minor axis of the
infrarenal neck was used to record neck diameter, but no
quantitation of neck angulation was made by the core
laboratory. Thus, in patients with angulated necks the
length of circumferential fixation of the stent graft to the
aortic neck would be overestimated with this technique
(Fig 1, C). Although the preoperative iliac length and
diameter were measured by the core laboratory, there was
no recording of post-deployment iliac stent position by the
core laboratory, and thus iliac fixation length could not be
calculated.
Results were expressed as mean plus or minus standard
deviation. Differences among groups were determined with
a t test and analysis of variance (ANOVA) for continuous
data, and g2 and Fisher exact tests for categorical data.
Time-dependent data were analyzed with the Kaplan-
Meier method, and were compared with the log-rank test.
Multivariate comparisons were performed with the Cox
proportional hazard model, accounting for potential risk
factors. P  .05 was considered significant.
RESULTS
Patient and aneurysm characteristics. Stent-graft
migration rate was reported at some time during follow-up
in 94 of 1119 patients; no migration was reported in 1025
patients. Mean time after implantation was 30  11
months (range, 0.5-61 months). There were no significant
differences between patients with (n 94) or without (n
1025) evidence of stent-graft migration with regard to age,
gender, or preoperative comorbid conditions or risk fac-
tors. There were no differences in preoperative AAA diam-
eter, or neck diameter or length between patients with or
without migration (Table I). Similarly, there were no sig-
nificant differences in patient characteristics or preoperative
aneurysm or neck morphologic features between the subset
of 387 Phase II patients with core laboratory measurements
and the overall patient cohort of 1119 patients, and no
significant differences in preoperative characteristics be-
tween patients with migration (n  47) and without mi-
gration (n  340) in the subset analysis.
Migration and endoleak. The number of patients
with migration increased with duration after device implan-
tation. At 6 months, 10 of 916 patients had migration, and
3 of these patients had an endoleak (2 type I, 1 type II). At
1 year, 19 of 886 patients had migration, and 5 of these
patients had an endoleak (2 type I, 1 type III, 2 type II). At
2 years, 36 of 499 patients had migration, and 9 of these
patients had endoleak (5 type I, 1 type III, 2 type II, 1
unknown type). At 3 years, 17 of 193 patients had migra-
tion, and 4 of these patients had endoleak (1 type III, 3
unknown type). At each time point, approximately 25% of
patients with migration had evidence of endoleak, mainly
type I or type III. There was no significant correlation
between stent-graft migration and the presence or absence
of endoleak on post-procedure CT scans.
Analysis with the Kaplan-Meier method. Three-
year Kaplan-Meier analysis for freedom from migration is
shown in Fig 2. Kaplan-Meier estimate for freedom from
migration for the entire cohort of 1119 patients was 98.6%
at 1 year, 93.4% at 2 years, and 81.2% at 3 years. Most
patients had not yet reached the 3-year follow-up, and 427
patients were at risk at the beginning of the 2-year to 3-year
interval and 135 patients were at risk at the end of the
3-year interval (Fig 2).
Stent-graft migration was reported in 47 of 387 pa-
tients in the subset of Phase II patients with core laboratory
data. Mean duration of device implant in this subset of
patients was 36  12 months (range, 1-58 months).
Kaplan-Meier analysis for freedom from migration for the
subset of 387 Phase II patients at 1 year was 98.6%, at 2
years was 93.8%, and at 3 years was 83.3%, with 253
Table I. Patient (N  1119) and aneurysm
characteristics, migration vs no migration
Migration
(n  94)
No migration
(n  1025) P
Age (y) 72 73 NS
Male/female (%) 88/12 89/11 NS
COPD 29 28 NS
Smoking 89 83 NS
Coronary artery disease (%) 43 55 NS
Diabetes mellitus (%) 11 12 NS
Hypertension (%) 65 65 NS
AAA diameter (cm) 5.8  1.1 5.6  1.0 NS
Neck diameter (cm) 2.3  0.2 2.2  0.3 NS
Neck length (cm) 2.7  1.5 2.8  1.2 NS
COPD, Chronic obstructive pulmonary disease; AAA, abdominal aortic
aneurysm; NS, not significant.
Fig 2. Kaplan-Meier analysis of freedom from migration. In inter-
val from 24 months to 36 months, 427 patients were at risk at start
of the interval (24 months) and 135 patients were at risk at end of
the interval (36 months).
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patients at risk at the beginning of the 2-year to 3-year
interval. There was no significant difference in Kaplan-
Meier migration analysis between the overall clinical trial
patient cohort and the subset of Phase II patients with core
laboratory data.
Device design. There was no significant difference in
migration rate between the 174 patients who received the
early “stiff” bifurcation design (migration in 10 of 95
patients at 3 years) and the 1019 patients who received the
current “flexible” bifurcation design (migration in 7 of 98
patients at 3 years; difference not significant).
Device oversizing. The preoperative aortic neck di-
ameter measured on CT scans was compared with the
diameter of the implanted stent graft to assess the degree of
stent-graft oversizing in relation to stent-graft migration.
Migration occurred in 25 of 222 patients (11%) with less
than 10% oversizing, 62 of 800 patients (8%) with 10% to
30% oversizing, and 6 of 60 patients (10%) with more than
30% oversizing. There was no significant difference in mi-
gration between patients with “correct” oversizing (10%-
30%, 8% of patients) compared with patients with “incor-
rect” oversizing (10% or 30%, 11% of patients;
difference not significant). The relation between migration
and degree of stent-graft oversizing is shown in Fig 3.
Proximal extender cuffs. Proximal aortic extender
cuffs were used in 202 of 1119 patients (18%) at stent-graft
implantation. One extender cuff was placed in 13% of
patients, two extender cuffs in 3% of patients, and three or
more extender cuffs in 1% of patients. Proximal extender
cuffs were often needed during the trial when intraopera-
tive migration of the bifurcation module occurred while
withdrawing the delivery system. Postoperative migration
was not significantly affected by the need to place a proxi-
mal extender cuff at initial treatment or the number of
extender cuffs used. Migration in patients with no proximal
extender cuffs was 8%, in those with one extender cuff was
7%, in those with two extender cuffs was 16%, and in those
with three or more extender cuffs was 9%.
Proximal stent-graft fixation. Core laboratory anal-
ysis of the subset of 387 patients revealed no significant
difference in infrarenal neck length between the 47 patients
with migration (2.7  1.3 cm) and the 340 patients with-
out migration (3.1  1.4 cm). However, in patients with
migration the distance from the lowermost renal artery to
the proximal end of the stent graft was 38% greater (1.1 
0.7 cm) than in patients without migration (0.8  0.6 cm;
P  .006), indicating lower initial deployment of the stent
graft (Table II). This resulted in a 30% shorter fixation
length of the stent graft to the infrarenal neck in patients
with migration (1.6  1.4 cm) compared with patients
without migration (2.3  1.4 cm; P  .005).
Migration rate was 19% in patients with fixation length
less than 1.0 cm (17 of 89 patients), 17% in patients with
fixation length 1.0 to 1.5 cm (8 of 46 patients), and 9% in
patients with fixation length greater than 1.5 cm (22 of 252
patients).
Migration rate in patients with fixation length less than
1.5 cm was twofold greater than in patients with fixation
length greater than 1.5 cm (P  .005). Migration rate in
patients with fixation length less than 1.0 cm was twofold
greater than in patients with fixation length greater than
1.0 cm (P  .02). The Kaplan-Meier estimate of risk for
migration at 3 years with fixation length less than 1.5 cm
was 22%, and migration risk with fixation length greater
than 1.5 cm was 14% (P  .007, log-rank test). The
Kaplan-Meier estimate of risk for migration at 3 years with
fixation length less than 1.0 cm was 23%, and migration risk
with fixation length greater than 1.0 cm was 15% (P .05,
log-rank test).
Migration rate and clinical site. There were signifi-
cant differences in migration rate (P  .001, ANOVA)
among the 13 Phase II clinical sites, ranging from 0% to
30% (mean, 12%  9.3%). Migration rate for the lowest
quartile was 6%, median migration rate was 8%, and migra-
tion rate for the highest quartile was 15% (Fig 4). The
number of patients who underwent treatment at these sites
ranged from 6 to 73 (mean, 30  20), with no clear
relationship between number of patients and migration rate
at that site. Treatment was administered at these same 13
sites in 989 of 1119 patients (88%) in the study. The
number of patients receiving treatment at these sites during
the entire clinical trial ranged from 10 to 179 (mean, 76),
with 3-year freedom from migration rate, according to
Kaplan Meier analysis, ranging from 68% to 100% among
sites. There was no relationship between number of pa-
tients treated at a clinical site and Kaplan-Meier freedom
Fig 3. Migration and stent graft oversizing. Oversizing is defined
as percent difference between preoperative aortic neck diameter
and diameter of proximal stent graft.
Table II. Proximal stent graft fixation: Core laboratory
CT measurements
Migration
(n  47)
No migration
(n  340) P
Neck length (cm) 2.7  1.3 3.1  1.4 NS
Renal artery to
proximal end of
stent graft (cm)
1.1  0.7 0.8  0.6 .006
Proximal fixation
length (cm)
1.6  1.4 2.3  1.4 .005
Values represent mean  SD.
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from migration estimate at 3 years. The Kaplan-Meier
estimate of freedom from migration at 3 years ranged from
68% to 90% (mean, 77%) at the three sites with the largest
patient enrollment (mean number of patients treated, 141),
where 67% of patients had fixation length greater than 1.5
cm. The Kaplan-Meier estimate of freedom from migration
at 3 years ranged from 89% to 96% (mean, 93%) for the
three sites with the lowest patient enrollment (mean num-
ber of patients treated, 20), where 87% of patients had
fixation length greater than 1.5 cm.
Predictors of migration. Univariate cox proportional
hazard results revealed that proximal fixation length (P 
.005) and renal artery to stent-graft distance (P  .001)
were significant predictors of risk for stent-graft migration.
Factors that were not significant predictors of migration at
univariate and multivariate analysis included age, gender,
risk factors and comorbid conditions, pre-implantation aor-
tic aneurysm size, pre-implantation aortic neck length,
pre-implantation aortic neck diameter, degree of device
oversizing or undersizing, correct versus incorrect oversiz-
ing, device type (stiff vs flexible), use of extender cuffs at
implantation, and post-procedure endoleak. Multivariate
analysis including both proximal fixation length and renal
artery to stent-graft distance yielded P values of .04 and .01,
and hazard ratios of 0.975 and 1.058, respectively. These
results indicate that both of these factors are independently
predictive of migration and that each millimeter increase in
length of fixation decreases the hazard of migration by 2.5%
and each millimeter increase in renal artery to stent-graft
distance increases the hazard of migration by 5.8%. How-
ever, there were significant differences in migration rate
among clinical centers. Adjusting the multivariate model
for clinical center results in P .007 for stent-graft fixation,
with a hazard ratio of 0.967, and P  .058 for renal artery
to stent-graft distance, with a hazard ratio of 1.044.
Clinical outcome. Among the 94 patients with stent
graft migration, one patient had aneurysm rupture and
underwent successful open surgical repair. Seven aneu-
rysms ruptured among the 1025 patients (0.7%) with no
stent-graft migration (not significant). Six patients under-
went elective surgical conversion because of migration,
with type I endoleak, with or without aneurysm enlarge-
ment; and one patient underwent emergent surgical con-
version because of rupture. Twenty-three of 94 patients
with migration (24%) underwent secondary endovascular
treatment, with placement of proximal modular stent-graft
extenders, with or without distal stent-graft extenders.
Thus 30 of 94 patients (32%) with migration underwent
treatment. There were no treatment-related or aneurysm-
related deaths. Sixty-four patients (68%) with migration
have not required treatment or secondary procedures, and
continue to be monitored with clinical follow-up and serial
imaging studies.
Treated versus untreated migration. There was no
significant difference between patients with migration, with
(n 30) or without (n 64) treatment, with regard to age,
gender, risk factors, or comorbid conditions. There were
no significant differences in preoperative aneurysm size,
aortic neck diameter, or aortic neck length between treated
patients and untreated patients (Table III). Proximal fixa-
tion length was shorter in patients with treatment (1.0 
1.2 cm) compared with patients without treatment (1.9 
1.4 cm; P  .05) patients. Treated patients had larger
aneurysms at the last follow-up (6.1 1.2 cm vs 5.5 1.1
cm; P  .05) and had more endoleaks (53% vs 11% of
patients; P  .0001), particularly type I endoleak, com-
pared with untreated patients. There was no difference in
time to discovery of migration in treated patients (21  9
months) compared with untreated patients (23  12
months), and no difference in duration of implant between
patients with treated migration (34  10 months) and
untreated migration (37  11 months). There have been
no deaths related to the aneurysm, stent graft, or migration
among either treated or untreated patients, and no differ-
ence in 3-year survival (Kaplan-Meier analysis) between
patients with treated migration (100%) and untreated mi-
gration (93%; not significant).
DISCUSSION
Documentation of aortic endograft migration after
successful aneurysm exclusion has raised substantial con-
cern regarding the long-term durability of endovascular
procedures to treat AAA.4-9 Continuous downward dis-
placement forces are exerted on all aortic devices by the
Fig 4. Rank order of migration at 13 Phase II clinical sites. There
was no relation between number of patients treated at each site and
migration rate.
Table III. Treated versus untreated migration
Treated
(n  30)
Untreated
(n  64) P
AAA diameter (cm) 5.7  1.1 5.8  1.0 NS
Neck diameter (cm) 2.2  0.2 2.3  0.3 NS
Neck length (cm) 2.3  1.5 2.8  1.4 NS
Fixation length (cm) 1.0  1.2 1.9  1.4 .05
AAA diameter at migration
(cm)
6.1  1.2 5.5  1.1 .05
Endoleak rate (%) 53 11 .0001
Time to migration (mo) 21  9 23  12 NS
Duration of implant (mo) 34  10 37  11 NS
AAA, Abdominal aortic aneurysm; NS, not significant.
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pulsatile nature of blood flow,17 with cumulative effects
over time. Thus it is not surprising that migration has been
noted with all endovascular aortic devices and with pros-
thetic aortic grafts placed at open surgery.18 There is no
evidence of permanent tissue bonding between the aorta
and implanted prosthetic devices, and prevention of distal
migration of aortic devices appears to depend on the con-
tinuing integrity of fixation mechanisms over both the
short and long terms. Mechanical fixation of the AneuRx
stent graft depends on radial and frictional forces of the
stent graft applied to the aortic neck, iliac arteries, and
modular junction, along with longitudinal columnar sup-
port provided by the stent graft. This study provides evi-
dence for the importance of proximal fixation length in
preventing migration. Although iliac fixation length and
columnar strength are also important, data regarding these
factors are beyond the scope of this study.
AneuRx stent-graft migration has been reported from
European centers in which patients received treatment
during the same time frame as the US AneuRx clinical trial
(1996-1999), with migration rates similar to those found
in the clinical trial patients. Tutein Nolthenius et al19
reported 128 patients who received the AneuRx stent graft,
of which 77 patients had minimum follow-up of 12
months. Stent-graft migration occurred in 6 patients, with
a 2-year migration rate of 10% at life table analysis and 42
patients at risk at 2 years. This is similar to the 7% migration
rate at 2 years at Kaplan-Meier analysis in our study. The
report by Cao et al4 of 148 patients noted migration in 17
of 113 patients followed up for 2 or more years. Migration
rate at life table analysis was 21% at 3 years, with 27 patients
at risk at this time point. This is similar to the 3-year
Kaplan-Meier migration rate of 19% found in our analysis.
A higher migration rate was reported by Conners et al,5
who reported AneuRx device migration in 15 of 91 patients
with a minimum of 1 year of follow-up, and found a
cumulative migration rate at 2 analysis of 42% (8 of 19
patients) at 3 years. This variability in migration reported by
individual centers outside the trial is consistent with our
finding of a significant difference in migration rate at vari-
ous centers in the multicenter clinical trial.
Stent-graft migration may result from a variety of
causes, which may act together or individually, including
patient selection, preoperative characteristics of the aneu-
rysm and aortic neck, characteristics and properties of the
endovascular device, precision of device deployment, post-
operative morphologic changes in the aneurysm, aortic
neck enlargement, and endoleak.20-24 AneuRx stent-graft
migration has been attributed to preoperative aneurysm
size,4 device oversizing,5 post-implantation aortic neck en-
largement,5 and use of a stiff device early in the clinical
trial.6 These were not found to be significant predictors of
migration in this study.
We found that low deployment of the stent graft, below
the renal arteries, and short proximal fixation length were
significant predictors of subsequent stent-graft migration.
Low deployment may be the result of poor patient selec-
tion, suboptimal imaging of the renal arteries during de-
ployment (poor image quality, angulation, lack of magnifi-
cation, movement, or parallax) or of downward
displacement of the primary bifurcation module during
retraction of the delivery system. Our finding of significant
differences in post-deployment migration rate among clin-
ical centers suggests that the technique and precision of
implantation are important to long-term effectiveness of
this device. Indeed, for each millimeter increase in distance
of the stent graft below the renal artery, the hazard of
migration increases by 5.8%, and for each millimeter in-
crease in proximal fixation length the hazard of migration
decreases by 2.5%. Preoperative aortic size, aortic neck
length, degree of device oversizing or undersizing, device
type (stiff vs flexible), use of proximal extender cuffs at
device implantation, and post-procedure endoleak were
not significant predictors of migration. This is not to say
that these factors are not clinically important; they simply
do not appear to predict subsequent stent-graft migration.
Cao et al4 similarly used univariate and multivariate
analysis to study AneuRx stent-graft migration, and found
no relation to device oversizing, preoperative aortic neck
diameter, length, angulation, thrombus, use of a stiff de-
vice, or presence of endoleak. In contrast to our results,
these authors did not find that deployment of the device
more than 10 mm below the renal artery was a significant
factor for migration, but identified neck enlargement
greater than 10% and preoperative aortic diameter greater
than 5.5 cm as independent risk factors for stent-graft
migration.
Our finding that short proximal fixation length of the
stent graft to the infrarenal neck was a significant predictor
of the likelihood of subsequent stent-graft migration is
consistent with clinical observations that poor stent-graft
fixation is a primary cause of clinical failure, resulting in
aneurysm rupture and need for secondary treatment or
conversion to open surgical repair.10,11,15,16,20,21,25,26
However, it should be noted that poor fixation can also
occur at the modular junction and iliac arteries, which were
not quantitatively studied in this core laboratory analysis.
The method used in this study to calculate length of
achieved fixation involved measuring the axial distance
from the lowermost renal artery to the top of the stent graft,
as seen on post-implantation CT scans, and subtracting it
from the length of the infrarenal neck as measured on axial
CT scans. Although this method may give an accurate
estimate of fixation length when the aneurysm and aortic
neck are straight, it is likely that effective fixation length is
overestimated if the aneurysm and aortic neck are signifi-
cantly angulated (Fig 1). Thus, true fixation length may
have been shorter than was calculated in this study. With
significant neck angulation, the superior aspect of the stent
graft may be in close proximity to the renal artery, and the
inferior aspect of the stent graft may have little contact with
the aneurysm neck, resulting in ineffective fixation and seal.
In this study we had no meaningful data on neck angulation
for analysis. However, short angulated necks with poor
stent-graft fixation are significant factors in aneurysm rup-
ture15 and predictors of adverse clinical events.20-22 This
JOURNAL OF VASCULAR SURGERY
Volume 38, Number 6 Zarins et al 1269
suggests that patients with angulated necks may require
longer infrarenal necks, compared with patients with
straight necks, for secure stent-graft fixation.
There were significant differences in migration rates
among clinical sites, being low at some sites and high at
other sites. Furthermore, we found no relation between
migration and number of patients treated at each site, and
migration rate for each center did not appear to change
over the course of the clinical trial. In this regard, it should
be noted that the primary end point for procedural success
during the trial was complete aneurysm exclusion with no
endoleak. Migration, however, is a late event, and often
does not appear for several years after implantation. Critical
information regarding long-term success of endovascular
aneurysm repair became known only after completion of
the clinical trial and therefore could not affect the learning
curve during the trial. Aneurysm rupture after successful
AneuRx device implantation was first reported in 1999 and
published in 2000, after all patients included in this report
had already undergone treatment.14,15 Failure analysis of
patients with rupture identified the primary cause of aneu-
rysm rupture to be poor fixation of the stent graft in the
aortic neck, iliac arteries, or bifurcation junction gate,15
rather than presence or absence of endoleak.26 A morpho-
logic analysis by Fillinger et al20 provided information that
aortic neck length and angulation, as well as proximal and
distal fixation length, are significant predictors of adverse
clinical events and the need for secondary procedures. This
information was provided to clinical investigators, and was
included in training sessions for new users of the device
after US Food and Drug Administration approval. Thus,
although patient selection criteria for the clinical trial in-
cluded patients with a 1.0-cm infrarenal neck length, the
current manufacturer’s instructions for use recommends a
1.5-cm infrarenal aortic neck length and avoidance of neck
angulation greater than 45 degrees. On the basis of knowl-
edge gained thus far, it is not known whether this “learning
curve,” after completion of the trial, has resulted in center-
specific reduction or overall reduction in migration rate.
Substantial improvements in intraoperative imaging
and device implantation techniques have evolved since
completion of the AneuRx clinical trial. Early technique
involved using a tabletop ruler to reference the renal arter-
ies, with no magnification or image intensifier angulation.
Current techniques involve high-resolution image intensi-
fiers, with magnification and angulation of the C-arm to
Fig 5. AneuRx stent graft placed during clinical trial, with complete aneurysm exclusion and no endoleak. Left, Low
positioning of stent graft in aortic neck, with short proximal fixation length and short iliac fixation length, are evident
on post-implantation CT scan (three-dimensional reconstruction). Right, Stent-graft migration with development of
type I endoleak and aneurysm enlargement, noted at 23 months, were successfully treated with placement of proximal
and distal extender cuffs. Current recommended clinical practice is to achieve fixation at initial endovascular treatment
by positioning the device just below the renal arteries and using iliac modules, as needed, to extend the device to the
level of the hypogastric arteries.
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precisely locate the renal arteries during deployment. These
techniques are now routinely used in most practices, but
were used only rarely at some clinical sites during the trial.
Improved techniques of buttressing or deployment of the
opposite iliac limb before pulling the runners on the main
bifurcation device,27,28 along with recent improvements in
the delivery system (expedient delivery system introduced
in 2002), have virtually eliminated downward migration of
the primary bifurcation module during device deployment.
This occurred commonly during the clinical trial, and fre-
quently required deployment of a proximal aortic extender
cuff to compensate for initial stent-graft deployment well
below the renal arteries. Although the frequency of ex-
tender cuff use at each clinical site was not a predictor of
subsequent migration, the current need for proximal ex-
tender cuffs at initial treatment appears to be substantially
less than during the clinical trial. Distal extension of the
stent graft with additional modules to the level of the iliac
bifurcation is now commonly performed, but was rarely
used during the clinical trial. Current awareness of the
importance of stent-graft fixation has likely resulted in
improved initial fixation of the stent graft compared with
the practice during the clinical trial (Fig 5).
The clinical significance of stent-graft migration is vari-
able. Most patients with migration in the AneuRx clinical
trial (68%) have required no treatment thus far. More than
half of the patients in the experience of Cao et al4 and two
thirds of the patients in the study by Conners et al have not
required treatment.5 In patients who require treatment,
such as those with type I endoleak or aneurysm enlarge-
ment, usually a proximal aortic extender cuff can be placed,
to the level of the lowermost renal artery. This was true in
77% of patients with stent-graft migration in the AneuRx
trial, with only 23% of treated patients needing surgical
conversion. Similarly, Cao et al were able to treat 75% of
patients with migration with aortic extender cuffs, and
open repair was required in only 2 patients.4 Conners et al5
and Tutein Nothenius et al19 were able to treat all migra-
tion with extender cuffs, with no need for surgical conver-
sion. These good results are likely due to careful and
ongoing surveillance, with prompt secondary treatment as
clinically indicated. It is possible that over time more pa-
tients in whom migration has been identified will require
secondary treatment.
The clinical experience of endovascular aneurysm repair
with the AneuRx stent graft is favorable. Three-year
Kaplan-Meier analysis of the primary end points in all 1193
patients treated during the course of the clinical trial reveals
low aneurysm rupture rate (1.6%), low aneurysm-related
death rate (3.1%), low surgical conversion rate (5.8%), and
overall survival of 76.6%.29
CONCLUSION
Device migration after endovascular aneurysm repair
with the AneuRx stent graft appears to be largely related to
precision of deployment of the stent graft just below the
renal arteries and the length of proximal fixation achieved
after device deployment, rather than to preoperative neck
length or aneurysm anatomy. This highlights the impor-
tance of the technical aspects of stent-graft deployment.
Improved intraoperative imaging and deployment tech-
niques, together with improved patient selection, may re-
sult in achieving increased length of proximal fixation at
device implantation. This, together with improved distal
iliac fixation, may lower migration rates. Most device mi-
gration can be treated with endovascular placement of
modular stent-graft extenders. The long-term outcome
after such treatment remains to be determined.
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INVITED COMMENTARY
James May, MD
The positive aspects of this multicenter trial are that it is
prospective, involves a large number of patients, and has had data
from one of its phases analyzed by an independent core laboratory.
The article is an important one, since the authors have previously
identified poor fixation as the cause of most ruptures following
endovascular repair with the AneuRx prosthesis.1 It is unfortunate,
therefore, that migration at modular connections and between the
prosthetic limbs and native iliac arteries was not addressed.
Since the article reports clinically significant events almost
entirely on the basis of imaging findings, it is regrettable that
details of imaging and methodology of measurement are not
included in the text. It is well known that parallax error in plain
radiographs makes detection of endograft migration by reference
to bony landmarks on images obtained at different times an unre-
liable method. Similarly, in the absence of any information on the
thickness of CT slices, the sensitivity of this modality in detecting
migration is called into question. The criteria by which the core
laboratory and clinical sites assigned the dichotomous endpoint of
migration or no migration are missing, together with information
on the intraobserver and interobserver error for measuring migra-
tion. Migration is defined by the authors as “any postimplantation
movement or displacement of the stent graft.” If this statement is
taken at face value, all 1025 patients categorized as having no
migration would have had to have follow-up imaging with the
endograft assigned the identical distance from the reference point
as in the postdeployment images, accurate to the last millimeter.
Information is also lacking on imaging data coming from partici-
pating clinical sites and not reviewed by the core laboratory. If
these data were not obtained under any defined protocol and were
produced by observers with variable skill levels, migration may
have been underreported.
Although the stated objective of the article is to identify factors
that may predispose to stent-graft migration, the relatively high
incidence of migration itself tends to overshadow the culprit
factors of low initial deployment of the device below the renal
arteries and a short proximal fixation length. The incidence of
migration documented in the article is a cause for some concern.
Two of the clinical sites had migration rates of 30% (Fig 4), while
Kaplan-Meier analysis demonstrates an increasing incidence with
time (18.8% at 3 years, Fig 2). Moreover, it should be noted that
the mean follow-up from implantation is limited to 23 months,
which is just short of a marked increase in events, and that 70% of
patients did not reach the 3-year follow-up time point. Since the
cut off date for this study was August 2001, surgeons and patients
will await with interest the authors’ next report.
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